Breakthrough cancer therapy developed at Penn receives 2nd FDA approval

The Food and Drug Administration on Tuesday approved a second indication for a revolutionary cancer therapy initially developed by researchers at the University of Pennsylvania's Abramson Cancer Center. The FDA cleared Kymriah, a personalized cellular therapy marketed by Novartis, for use in patients with advanced non-Hodgkin's lymphoma. The FDA specifically approved Kymriah for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible fo r…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news